<li>alosetron<p>sulfamethoxazole will increase the level or effect of alosetron by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>amiloride<p>amiloride, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.<span><br><br></span>amiloride increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>amiloride, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.</p></li><li>aminohippurate sodium<p>sulfamethoxazole, aminohippurate sodium. Other (see comment). Minor/Significance Unknown. 
Comment: This substance interferes with chemical color development of aminohippurate (PAH) essential to accurate renal clearance analysis.</p></li><li>azithromycin<p>azithromycin and trimethoprim both increase  QTc interval. Minor/Significance Unknown.</p></li><li>amiodarone<p>amiodarone will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>amitriptyline<p>sulfamethoxazole decreases levels of amitriptyline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>amobarbital<p>amobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>amoxapine<p>sulfamethoxazole decreases levels of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>aspirin rectal<p>aspirin rectal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>aspirin/citric acid/sodium bicarbonate<p>aspirin/citric acid/sodium bicarbonate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>azathioprine<p>sulfamethoxazole, azathioprine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Leukopenia due to additive myelosuppression.</p></li><li>azithromycin<p>azithromycin and sulfamethoxazole both increase  QTc interval. Minor/Significance Unknown.</p></li><li>balsalazide<p>sulfamethoxazole will decrease the level or effect of balsalazide by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.<span><br><br></span>balsalazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>trimethoprim will decrease the level or effect of balsalazide by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>bendroflumethiazide<p>bendroflumethiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>bendroflumethiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>bendroflumethiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>biotin<p>sulfamethoxazole will decrease the level or effect of biotin by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.<span><br><br></span>trimethoprim will decrease the level or effect of biotin by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>bosentan<p>sulfamethoxazole will increase the level or effect of bosentan by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>chlorothiazide<p>chlorothiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>bumetanide<p>bumetanide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>butabarbital<p>butabarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>butalbital<p>butalbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>carbamazepine<p>carbamazepine will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>celecoxib<p>sulfamethoxazole will increase the level or effect of celecoxib by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>chlorothiazide<p>chlorothiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>chlorothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>chlorthalidone<p>chlorthalidone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>chlorthalidone, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>chlorthalidone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>choline magnesium trisalicylate<p>choline magnesium trisalicylate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>cyclopenthiazide<p>cyclopenthiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>cimetidine<p>cimetidine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>clomipramine<p>sulfamethoxazole decreases levels of clomipramine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>cyclopenthiazide<p>cyclopenthiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>cyclopenthiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>dapsone<p>trimethoprim, dapsone.
Either increases levels of the other by decreasing elimination. Minor/Significance Unknown.<span><br><br></span>sulfamethoxazole, dapsone.
Either increases levels of the other by decreasing elimination. Minor/Significance Unknown.</p></li><li>dapsone topical<p>trimethoprim increases levels of dapsone topical by unspecified interaction mechanism. Minor/Significance Unknown. Coadministration increases systemic exposure of dapsone and its metabolites (N-acetyl-dapsone, dapsone hydroxylamine).<span><br><br></span>sulfamethoxazole increases levels of dapsone topical by unspecified interaction mechanism. Minor/Significance Unknown. Coadministration increases systemic exposure of dapsone and its metabolites (N-acetyl-dapsone, dapsone hydroxylamine).</p></li><li>desipramine<p>sulfamethoxazole decreases levels of desipramine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>diltiazem<p>diltiazem will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>diclofenac<p>sulfamethoxazole will increase the level or effect of diclofenac by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>diflunisal<p>diflunisal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>diltiazem<p>sulfamethoxazole will increase the level or effect of diltiazem by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>disulfiram<p>disulfiram will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>divalproex sodium<p>divalproex sodium will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>dosulepin<p>sulfamethoxazole decreases levels of dosulepin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>doxepin<p>sulfamethoxazole decreases levels of doxepin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>drospirenone<p>drospirenone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.<span><br><br></span>drospirenone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>drospirenone, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.</p></li><li>ethacrynic acid<p>ethacrynic acid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>hydrochlorothiazide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>ethotoin<p>sulfamethoxazole increases levels of ethotoin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>etravirine<p>etravirine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>felbamate<p>felbamate will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>fluconazole<p>fluconazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>flurbiprofen<p>sulfamethoxazole will increase the level or effect of flurbiprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>fluvastatin<p>sulfamethoxazole will increase the level or effect of fluvastatin by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>folic acid<p>sulfamethoxazole decreases levels of folic acid by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>fosphenytoin<p>sulfamethoxazole increases levels of fosphenytoin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>furosemide<p>furosemide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>ganciclovir<p>ganciclovir increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>hexobarbital<p>hexobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>hydrochlorothiazide<p>sulfamethoxazole will increase the level or effect of hydrochlorothiazide by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>hydrochlorothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>ibuprofen<p>sulfamethoxazole will increase the level or effect of ibuprofen by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>imipramine<p>sulfamethoxazole decreases levels of imipramine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>indapamide<p>indapamide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>indapamide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>indapamide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>indomethacin<p>indomethacin increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>memantine<p>memantine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>isocarboxazid<p>isocarboxazid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>itraconazole<p>itraconazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>ketoconazole<p>ketoconazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>l-methylfolate<p>sulfamethoxazole decreases levels of l-methylfolate by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>lamivudine<p>sulfamethoxazole increases levels of lamivudine by decreasing renal clearance. Minor/Significance Unknown.</p></li><li>leflunomide<p>leflunomide will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>linezolid<p>linezolid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>lofepramine<p>sulfamethoxazole decreases levels of lofepramine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>losartan<p>sulfamethoxazole decreases effects of losartan by decreasing metabolism. Minor/Significance Unknown. May inhibit the conversion of losartan to its active metabolite E-3174. Importance of interaction not established; monitor individual therapeutic response to determine losartan dosage.</p></li><li>maprotiline<p>sulfamethoxazole decreases levels of maprotiline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>meloxicam<p>sulfamethoxazole will increase the level or effect of meloxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>memantine<p>sulfamethoxazole will increase the level or effect of memantine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>mephobarbital<p>mephobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>mesalamine<p>mesalamine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>metformin<p>metformin will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>sulfamethoxazole will increase the level or effect of metformin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>methyclothiazide<p>methyclothiazide, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>sulfamethoxazole will increase the level or effect of methyclothiazide by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>methyclothiazide, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>methyclothiazide will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>metolazone<p>metolazone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>metolazone, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.<span><br><br></span>metolazone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of hyponatremia.</p></li><li>metronidazole<p>metronidazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>midodrine<p>midodrine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>mianserin<p>sulfamethoxazole decreases levels of mianserin by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>miconazole vaginal<p>miconazole vaginal will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>midodrine<p>sulfamethoxazole will increase the level or effect of midodrine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>mineral oil<p>mineral oil decreases levels of sulfamethoxazole by inhibition of GI absorption. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>nateglinide<p>nateglinide will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>nilotinib<p>nilotinib will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>nitazoxanide<p>nitazoxanide, sulfamethoxazole.
Either increases levels of the other by Mechanism: plasma protein binding competition. Minor/Significance Unknown.</p></li><li>nortriptyline<p>sulfamethoxazole decreases levels of nortriptyline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>ofloxacin<p>sulfamethoxazole will increase the level or effect of ofloxacin by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>ofloxacin will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>omeprazole<p>omeprazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>pantothenic acid<p>trimethoprim will decrease the level or effect of pantothenic acid by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>pantothenic acid<p>sulfamethoxazole will decrease the level or effect of pantothenic acid by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>pazopanib<p>sulfamethoxazole and pazopanib both increase  QTc interval. Minor/Significance Unknown.</p></li><li>pentobarbital<p>pentobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>phenelzine<p>phenelzine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>phenobarbital<p>phenobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>phenytoin<p>sulfamethoxazole increases levels of phenytoin by decreasing metabolism. Minor/Significance Unknown.</p></li><li>pimozide<p>sulfamethoxazole decreases levels of pimozide by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>piroxicam<p>sulfamethoxazole will increase the level or effect of piroxicam by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>primaquine<p>primaquine, sulfamethoxazole. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Risk of hemolysis in G6PD deficient pts.</p></li><li>primidone<p>primidone will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>probenecid<p>probenecid increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>protriptyline<p>sulfamethoxazole decreases levels of protriptyline by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>pyridoxine<p>trimethoprim will decrease the level or effect of pyridoxine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.<span><br><br></span>sulfamethoxazole will decrease the level or effect of pyridoxine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>pyridoxine (antidote)<p>sulfamethoxazole will decrease the level or effect of pyridoxine (antidote) by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.<span><br><br></span>trimethoprim will decrease the level or effect of pyridoxine (antidote) by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>pyrimethamine<p>sulfamethoxazole, pyrimethamine. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased bone marrow toxicity.</p></li><li>quinine<p>quinine will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>quinine<p>sulfamethoxazole will increase the level or effect of quinine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>ramelteon<p>sulfamethoxazole will increase the level or effect of ramelteon by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>ranitidine<p>sulfamethoxazole will increase the level or effect of ranitidine by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>rifampin<p>rifampin will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>rifapentine<p>rifapentine will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>salicylates (non-asa)<p>salicylates (non-asa) increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>salsalate<p>salsalate increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>secobarbital<p>secobarbital will decrease the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>selegiline transdermal<p>selegiline transdermal increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>sitaxentan<p>sitaxentan will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>spironolactone<p>spironolactone increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.<span><br><br></span>spironolactone, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.<span><br><br></span>spironolactone, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.</p></li><li>sulfamethoxazole<p>sulfamethoxazole will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>sulfasalazine<p>sulfasalazine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>thiamine<p>sulfamethoxazole will decrease the level or effect of thiamine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.<span><br><br></span>trimethoprim will decrease the level or effect of thiamine by  altering intestinal flora. Applies only to oral form of both agents. Minor/Significance Unknown.</p></li><li>ticlopidine<p>ticlopidine will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>triamterene<p>triamterene will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, trimethoprim. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.</p></li><li>tolbutamide<p>sulfamethoxazole will increase the level or effect of tolbutamide by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>torsemide<p>torsemide increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>tranylcypromine<p>tranylcypromine increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>trazodone<p>sulfamethoxazole decreases levels of trazodone by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>triamterene<p>sulfamethoxazole will increase the level or effect of triamterene by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>triamterene, sulfamethoxazole. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Hyperkalemia.<span><br><br></span>triamterene increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>trimethoprim<p>sulfamethoxazole will increase the level or effect of trimethoprim by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>trimipramine<p>sulfamethoxazole decreases levels of trimipramine by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>valganciclovir<p>valganciclovir increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.</p></li><li>valproic acid<p>valproic acid will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>verapamil<p>trimethoprim will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.<span><br><br></span>sulfamethoxazole will increase the level or effect of verapamil by  basic (cationic) drug competition for renal tubular clearance. Minor/Significance Unknown.</p></li><li>verteporfin<p>sulfamethoxazole, verteporfin. Mechanism: pharmacodynamic synergism. Minor/Significance Unknown. Increased phototoxicity.</p></li><li>voriconazole<p>sulfamethoxazole will increase the level or effect of voriconazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.<span><br><br></span>voriconazole will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>willow bark<p>willow bark increases levels of sulfamethoxazole by unspecified interaction mechanism. Minor/Significance Unknown.</p></li><li>zafirlukast<p>zafirlukast will increase the level or effect of sulfamethoxazole by  affecting hepatic enzyme CYP2C9/10 metabolism. Minor/Significance Unknown.</p></li><li>zidovudine<p>zidovudine increases toxicity of sulfamethoxazole by pharmacodynamic synergism. Minor/Significance Unknown.<span><br><br></span>sulfamethoxazole increases levels of zidovudine by decreasing renal clearance. Minor/Significance Unknown.</p></li>